CU06-1004

Curacle Co., Ltd. · Phase 2 active Small molecule

At a glance

Generic name	CU06-1004
Also known as	SAC-1004, CU06, CU06-RE, Riverstat
Sponsor	Curacle Co., Ltd.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Study of CU06-1004 in Patients With Daibetic Macular Edema (PHASE2)
The Study of CU06-1004 in Patients With Diabetic Macular Edema (DME) (PHASE2)
First-In-Human Study of CU06-1004 Following Single and Multiple Ascending Doses in Healthy Volunteers (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

CU06-1004 CI brief — competitive landscape report
CU06-1004 updates RSS · CI watch RSS
Curacle Co., Ltd. portfolio CI